Immunic announces first patient enrolled in investigator-sponsored phase 2 clinical trial of vidofludimus calcium in patients with post covid syndrome

– investigator study sponsored by goethe university frankfurt (germany), funded via a german government grant; study drug vidofludimus calcium provided by immunic – – in addition to post covid readouts, study designed to deliver important data on the activity of vidofludimus calcium suppressing epstein-barr virus reactivation and related fatigue symptoms; third-party research identified epstein-barr virus r eactivation as potential cause for post covid fatigue – – severe fatigue also a common and debilitating symptom for multiple sclerosis patients with no effective therapies available; potential read-through to immunic's multiple sclerosis development program – new york , sept. 4, 2024 /prnewswire/ --  immunic, inc.  (nasdaq: imux), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced enrollment of the first patient in an investigator-sponsored phase 2 clinical trial of its lead asset, nuclear receptor related 1 (nurr1) activator, vidofludimus calcium (imu-838), entitled, "randomized adaptive assessment of post covid syndrome treatments_reducing inflammatory activity in patients with post covid syndrome (rapid­­_revive).
IMUX Ratings Summary
IMUX Quant Ranking